Comparison of new modality of treatment of TARE vs TACE, which is already accepted norm of treatment in the management of intermediate Liver Cancer : A 1st type of new Trial

Not Applicable

• Conditions: Health Condition 1: null- Hepatocellular Carcinoma

• Registration Number: CTRI/2017/08/009526
• Lead Sponsor: Department of Gastroenterology AIIMS New Delhi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Written informed consent provided

2.Aged >=18 years

3.AASLD criteria for diagnosis of HCC.

4.BCLC stage A and B.

5.ECOG performance status 0

6.Hemoglobin >= 9 g/dl, neutrophils >=1,500/mm3 and platelets >=50,000/mm3

7.Normal kidney function tests: Serum creatinine < 1.0 mg/dl

8.Bilirubin <= 1mg/dl, AST or ALT <= 5 x ULN (ULN: 40 IU/L), INR <= 1.5

9.Child-Pugh class A-B

Exclusion Criteria

1.Extra hepatic metastases

2.Previously treated HCC

3.Advanced liver disease with a Child-Pugh score C or active gastrointestinal bleeding or encephalopathy or refractory ascites

4.Pregnant or breastfeeding women

5.Allergy to contrast agents

6.Contraindication to hepatic artery catheterization, such as severe peripheral arterial disease precluding catheterization

7.Mental illness or other psychological disorder affecting the informed consent

8.Patient unable or unwilling to comply with the treatment and follow-up required by the study

9.Unable to take oral medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified